리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2025년 06월
페이지 정보:영문 284 Pages
라이선스 & 가격 (부가세 별도)
한글목차
결핵 진단 세계 시장은 2030년까지 26억 달러에 달할 전망
2024년에 22억 달러로 추정되는 결핵 진단 세계 시장은 2024년부터 2030년까지 CAGR 2.8%로 성장하여 2030년에는 26억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 배양에 기반한 진단은 CAGR 1.9%를 기록하며 분석 기간 종료까지 11억 달러에 달할 것으로 예측됩니다. 객담 검사 부문의 성장률은 분석 기간 동안 CAGR 3.7%로 추정됩니다.
미국 시장은 6억 140만 달러로 추정, 중국은 CAGR 5.1%로 성장 예측
미국의 결핵 진단 시장은 2024년에 6억 140만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 분석 기간인 2024-2030년 CAGR 5.1%로 2030년까지 5억 30만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 1.1%와 2.0%로 예측됩니다. 유럽에서는 독일이 CAGR 1.5%로 성장할 것으로 예측됩니다.
세계의 결핵 진단 시장 - 주요 동향과 촉진요인 정리
왜 결핵은 21세기에도 여전히 진단이 어려운가?
결핵은 예방과 치료가 가능한 질병임에도 불구하고, 특히 중저소득 국가에서 공중보건의 큰 도전이 되고 있습니다. 전 세계 결핵 퇴치에서 가장 큰 어려움 중 하나는 특히 어린이, HIV 감염자, 오지나 자원이 부족한 지역의 사람들과 같은 취약 계층에서 결핵을 적시에 정확하게 진단하는 것입니다. 객담 도말 현미경 검사와 같이 널리 사용되는 전통적인 방법은 특히 폐외 결핵이나 잠복 결핵의 경우 민감도가 낮다는 문제가 있습니다. 또한, 배양법은 시간이 오래 걸리고, 많은 발병 지역에서는 인프라와 숙련된 인력이 제한되어 있기 때문에 고급 진단 솔루션을 대규모로 시행하기 어렵습니다. 결핵의 다양한 임상 증상과 다른 호흡기질환과의 유사성은 진단을 더욱 복잡하게 만들고, 종종 오진이나 치료 지연으로 이어집니다. 이러한 제약으로 인해 감염과 치료의 간극을 좁히기 위해 보다 신속하고 정확하며 접근하기 쉬운 진단 기술이 시급히 요구되고 있습니다.
새로운 기술은 결핵 진단 상황을 어떻게 파괴하고 있는가?
최근 결핵을 보다 빠르고, 정확하고, 쉽게 검출할 수 있는 진단기술의 혁신이 폭발적으로 진행되고 있습니다. 특히 GeneXpert나 Truenat과 같은 핵산 증폭검사(NAAT)와 같은 분자진단 툴은 결핵과 다제내성 결핵(MDR-TB)을 몇 시간 내에 검출할 수 있는 능력을 크게 향상시켰습니다. 이러한 현장 진료소 및 농촌 보건소에서 복잡한 검사 인프라 없이도 신속한 진단을 가능하게 하는 현장 진료소 및 농촌 보건소에 도입되고 있으며, NAAT 외에도 인터페론-γ 방출 측정법(IGRA) 및 결핵 LAM 항원 검사 등 획기적인 기술을 통해 특히 HIV 감염자 및 소아 환경에서의 결핵 진단이 가능해졌습니다. HIV 감염자 및 소아 환경에서의 진단 선택권이 넓어지고 있습니다. 인공지능은 흉부 엑스레이 판독을 개선하고 디지털 진단 플랫폼은 검체 추적, 데이터 기록, 역학 매핑을 개선하는 데에도 적용되고 있습니다. 진단과 모바일 헬스 솔루션의 결합은 원격진료, 후속 조치 및 의사결정의 중앙 집중화를 가능하게 하며, 결핵 발병률이 높고 의료 시스템이 분절된 국가에서 특히 유용합니다.
전 세계 보편적 건강보장 추진이 결핵 진단에 대한 접근성에 영향을 미치고 있는가?
보편적 건강보장(UHC)을 향한 전 세계적인 움직임과 유엔의 결핵 퇴치 전략은 결핵 퇴치를 위한 기본 단계로서 각국 정부와 국제기구에 진단 접근성을 개선하도록 압력을 가하고 있으며, WHO, 세계기금, UNITAID와 같은 다자간 기구들은 진단 툴의 개발, 조달, 배포에 적극적으로 자금을 지원하고 있습니다. 각국의 결핵 프로그램은 조기 발견을 보다 현실적이고 분산된 방식으로 실현하기 위해 일차 의료 센터에 신속 분자진단법을 통합하도록 장려하고 있습니다. 이와 함께 저렴한 진단 키트를 개발하고 공급망의 병목현상을 극복하기 위해 현지 제조 역량을 개발하기 위한 민관 파트너십이 생겨나고 있습니다. 그러나 도시와 농촌의 격차, 가격의 형평성 문제로 인해 진단의 형평성 문제는 여전히 과제로 남아있습니다. 일부 정부는 결핵 검사와 HIV, COVID-19, 간염 검진을 결합한 종합적인 질병 검사 플랫폼을 채택하여 검진율을 높일 뿐만 아니라 의료 시스템의 효율성을 향상시킵니다. 이러한 다중 질병 검사 프레임워크는 고위험군 결핵 진단의 보급을 촉진할 것으로 기대됩니다.
결핵 진단 시장의 성장 원동력은?
결핵 진단 시장의 성장은 인구 밀집도가 높은 고위험 지역의 결핵 발병률 증가, 전염병 관리에 대한 공중 보건 투자 증가, 분자진단 툴의 급속한 보급 등 여러 요인에 기인합니다. 지역 진료소 및 이동 진료소에서 현장 검사에 대한 선호도가 높아지는 등 최종 사용 행태가 휴대용 신속 진단에 대한 수요를 증가시키고 있습니다. 또한, 약제 내성 결핵균주의 출현으로 결핵 병원체와 함께 내성 마커를 검출할 수 있는 첨단 분자 플랫폼의 채택이 증가하고 있습니다. 세계보건기구(WHO)와 각국 정부의 재정 지원도 아프리카, 동남아시아, 동유럽 등 결핵이 유행하는 국가에서 진단 툴의 보급을 가속화하고 있습니다. 멀티플렉스 검사, 샘플 풀, 자동 결과 해석과 같은 기술 동향은 운영의 확장성을 더욱 높여주고 있습니다. 소비자 행동도 변화하고 있으며, 코로나 이후 결핵 증상과 검사 수단에 대한 인식이 높아져 조기 진단에 대한 적극성이 높아지고 있습니다.
부문
유형(배양 기반 진단, 객담 검사, 신속 분자진단, 기타 유형), 최종사용자(병원, 진단 실험실, 기타 최종사용자)
조사 대상 기업 사례(총 44개사)
Abbott Laboratories
AdvaCare Pharma
Becton, Dickinson and Company(BD)
bioMerieux SA
Cepheid(Danaher Corporation)
DiaSorin S.p.A.
FIND(Foundation for Innovative New Diagnostics)
F. Hoffmann-La Roche AG
Hain Lifescience GmbH
Hologic, Inc.
JN-International Medical Corporation
Lionex GmbH
Lupin Limited
Novosibirsk TB Research Institute
Oxford Immunotec Ltd.
QIAGEN N.V.
R-Biopharm AG
Serum Institute of India Pvt. Ltd.
Thermo Fisher Scientific Inc.
Trivitron Healthcare
관세 영향 계수
Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 인위적인 매출원가 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.
Global Industry Analysts는 세계 주요 수석 이코노미스트(1,4,949명), 싱크탱크(62개 기관), 무역 및 산업 단체(171개 기관)의 전문가들의 의견을 면밀히 검토하여 생태계에 미치는 영향을 평가하고 새로운 시장 현실에 대응하고 있습니다. 모든 주요 국가의 전문가와 경제학자들이 관세와 그것이 자국에 미치는 영향에 대한 의견을 추적 조사하고 있습니다.
Global Industry Analysts는 이러한 혼란이 향후 2-3개월 내에 마무리되고 새로운 세계 질서가 보다 명확하게 확립될 것으로 예상하고 있으며, Global Industry Analysts는 이러한 상황을 실시간으로 추적하고 있습니다.
2025년 4월 : 협상 단계
이번 4월 보고서에서는 관세가 세계 시장 전체에 미치는 영향과 지역별 시장 조정에 대해 소개합니다. 당사의 예측은 과거 데이터와 진화하는 시장 영향요인을 기반으로 합니다.
2025년 7월 : 최종 관세 재설정
고객님들께는 각 국가별 최종 리셋이 발표된 후 7월에 무료 업데이트 버전을 제공해 드립니다. 최종 업데이트 버전에는 명확하게 정의된 관세 영향 분석이 포함되어 있습니다.
상호 및 양자 간 무역과 관세의 영향 분석:
미국 <> 중국 <> 멕시코 <> 캐나다 <> EU <> 일본 <> 인도 <> 기타 176개국
업계 최고의 이코노미스트 : Global Industry Analysts의 지식 기반은 국가, 싱크탱크, 무역 및 산업 단체, 대기업, 그리고 세계 계량 경제 상황의 전례 없는 패러다임 전환의 영향을 공유하는 분야별 전문가 등 가장 영향력 있는 수석 이코노미스트를 포함한 14,949명의 이코노미스트를 추적하고 있습니다. 16,491개 이상의 보고서 대부분에 마일스톤에 기반한 2단계 출시 일정이 적용되어 있습니다.
목차
제1장 조사 방법
제2장 주요 요약
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
스페인
러시아
기타 유럽
아시아태평양
호주
인도
한국
기타 아시아태평양
라틴아메리카
아르헨티나
브라질
멕시코
기타 라틴아메리카
중동
이란
이스라엘
사우디아라비아
아랍에미리트
기타 중동
아프리카
제4장 경쟁
KSM
영문 목차
영문목차
Global Tuberculosis Diagnostics Market to Reach US$2.6 Billion by 2030
The global market for Tuberculosis Diagnostics estimated at US$2.2 Billion in the year 2024, is expected to reach US$2.6 Billion by 2030, growing at a CAGR of 2.8% over the analysis period 2024-2030. Culture based Diagnosis, one of the segments analyzed in the report, is expected to record a 1.9% CAGR and reach US$1.1 Billion by the end of the analysis period. Growth in the Sputum Test segment is estimated at 3.7% CAGR over the analysis period.
The U.S. Market is Estimated at US$601.4 Million While China is Forecast to Grow at 5.1% CAGR
The Tuberculosis Diagnostics market in the U.S. is estimated at US$601.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$500.3 Million by the year 2030 trailing a CAGR of 5.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.1% and 2.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.5% CAGR.
Global Tuberculosis Diagnostics Market - Key Trends & Drivers Summarized
Why Is Tuberculosis Still a Diagnostic Challenge in the 21st Century?
Despite being a preventable and curable disease, tuberculosis (TB) continues to pose a major public health challenge, especially in low- and middle-income countries. One of the biggest hurdles in the global fight against TB is the timely and accurate diagnosis of the disease, particularly among vulnerable populations such as children, people living with HIV, and individuals in remote or under-resourced areas. Traditional methods like sputum smear microscopy, though widely used, suffer from low sensitivity, especially in cases of extrapulmonary and latent TB. Moreover, the long turnaround time associated with culture methods and the limitations in infrastructure and skilled personnel in many endemic regions make advanced diagnostic solutions difficult to implement at scale. TB's variable clinical manifestations and similarities with other respiratory illnesses further complicate diagnosis, often leading to misdiagnosis or delayed treatment. These limitations underscore the urgent need for faster, more accurate, and accessible diagnostic technologies to help bridge the gap between infection and intervention.
How Are New Technologies Disrupting the Diagnostic Landscape for TB?
Recent years have seen an explosion in diagnostic innovations aimed at making TB detection faster, more accurate, and accessible. Molecular diagnostic tools, particularly nucleic acid amplification tests (NAATs) like GeneXpert and Truenat, have significantly improved the ability to detect TB and multidrug-resistant TB (MDR-TB) within hours. These point-of-care technologies are being deployed in field clinics and rural health centers, where they allow for rapid diagnosis without the need for complex lab infrastructure. In addition to NAATs, other breakthroughs such as interferon-gamma release assays (IGRAs) and TB LAM antigen tests are expanding diagnostic options, especially for people with HIV or in pediatric settings. Artificial intelligence is also being applied to enhance chest X-ray interpretation, while digital diagnostic platforms are improving sample tracking, data recording, and epidemiological mapping. The convergence of diagnostics with mobile health solutions enables remote consultations, follow-ups, and centralized decision-making, particularly valuable in countries with high TB burdens and fragmented healthcare systems.
Is the Global Push for Universal Health Coverage Influencing TB Diagnostic Access?
The global movement toward Universal Health Coverage (UHC) and the United Nations' End TB Strategy are exerting pressure on governments and international agencies to improve diagnostic access as a fundamental step toward eradication. Multilateral organizations like the WHO, Global Fund, and UNITAID are actively funding diagnostic tool development, procurement, and distribution, with a focus on affordability and scalability. National TB programs are being urged to integrate rapid molecular diagnostics into primary healthcare centers, making early detection more feasible and decentralized. In parallel, public-private partnerships are emerging to develop affordable diagnostic kits and local manufacturing capacities to overcome supply chain bottlenecks. However, diagnostic equity remains a challenge, with urban-rural disparities and affordability issues limiting reach. Some governments are adopting integrated disease testing platforms that combine TB testing with HIV, COVID-19, and hepatitis screening, which not only enhances detection but also improves healthcare system efficiency. These multi-disease testing frameworks are expected to drive increased uptake of TB diagnostics across high-risk populations.
What Is Driving Growth in the Tuberculosis Diagnostics Market?
The growth in the tuberculosis diagnostics market is driven by several factors, including the rising global TB incidence in densely populated and high-risk regions, increasing public health investments in infectious disease management, and rapid adoption of molecular diagnostic tools. End-use behavior, such as a growing preference for point-of-care testing in community clinics and mobile health units, is pushing the demand for portable, rapid diagnostics. Additionally, the emergence of drug-resistant TB strains has led to increased adoption of advanced molecular platforms capable of detecting resistance markers alongside TB pathogens. Funding from global health bodies and national governments is also accelerating the deployment of diagnostic tools, especially in endemic countries in Africa, Southeast Asia, and Eastern Europe. Technological trends such as multiplex testing, sample pooling, and automated result interpretation are further enhancing operational scalability. Consumer behavior is also shifting, with heightened awareness about TB symptoms and testing avenues post-COVID, making individuals more proactive in seeking early diagnosis - a factor that will continue to fuel diagnostic volumes globally.
SCOPE OF STUDY:
The report analyzes the Tuberculosis Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Type (Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis, Other Types); End-Use (Hospitals, Diagnostic Labs, Other End-Uses)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 44 Featured) -
Abbott Laboratories
AdvaCare Pharma
Becton, Dickinson and Company (BD)
bioMerieux SA
Cepheid (Danaher Corporation)
DiaSorin S.p.A.
FIND (Foundation for Innovative New Diagnostics)
F. Hoffmann-La Roche AG
Hain Lifescience GmbH
Hologic, Inc.
JN-International Medical Corporation
Lionex GmbH
Lupin Limited
Novosibirsk TB Research Institute
Oxford Immunotec Ltd.
QIAGEN N.V.
R-Biopharm AG
Serum Institute of India Pvt. Ltd.
Thermo Fisher Scientific Inc.
Trivitron Healthcare
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.
We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.
As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.
To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!
APRIL 2025: NEGOTIATION PHASE
Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.
JULY 2025 FINAL TARIFF RESET
Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.
Reciprocal and Bilateral Trade & Tariff Impact Analyses:
USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.
Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.
COMPLIMENTARY PREVIEW
Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Tuberculosis Diagnostics - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Adoption of Rapid Molecular Testing Platforms Drives Early Detection and Case Management
Increasing Focus on Drug-Resistant TB Surveillance Strengthens Market Need for Genotypic Tools
Integration of AI in X-Ray Screening Expands Diagnostic Reach in Resource-Limited Settings
Public Health Funding and Global Donor Programs Propel Growth of Point-of-Care Diagnostics
Shift Toward Decentralized Testing Models Drives Demand for Portable and Compact Devices
Rising Co-Infection with HIV Accelerates Demand for Dual and Multiplex Testing Kits
Government Mandates for TB Case Notification Systems Spur Diagnostic Infrastructure Investments
Regulatory Approvals for Novel Antigen-Based Tests Expand Testing in Pediatric Populations
Expansion of Mobile and Remote Diagnostic Units Sustains Outreach in Rural Areas
Inclusion of TB Testing in Universal Health Coverage Expands Access and Market Size
Digital Reporting and Sample Tracking Platforms Drive Operational Efficiency in Testing Labs
Demand for Cost-Effective, High-Sensitivity Tools Creates Market Entry Opportunities for Local Players
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Tuberculosis Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 3: World Historic Review for Tuberculosis Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 4: World 15-Year Perspective for Tuberculosis Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Culture based Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 6: World Historic Review for Culture based Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 7: World 15-Year Perspective for Culture based Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Sputum Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 9: World Historic Review for Sputum Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 10: World 15-Year Perspective for Sputum Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Rapid Molecular Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 12: World Historic Review for Rapid Molecular Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 13: World 15-Year Perspective for Rapid Molecular Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 15: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 16: World 15-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 18: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 19: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Diagnostic Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 21: World Historic Review for Diagnostic Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 22: World 15-Year Perspective for Diagnostic Labs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 24: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 25: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Tuberculosis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 26: USA Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 27: USA Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 28: USA 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
TABLE 29: USA Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 30: USA Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 31: USA 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
CANADA
TABLE 32: Canada Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 33: Canada Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 34: Canada 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
TABLE 35: Canada Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 36: Canada Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 37: Canada 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
JAPAN
Tuberculosis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 38: Japan Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 39: Japan Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 40: Japan 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
TABLE 41: Japan Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 42: Japan Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 43: Japan 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
CHINA
Tuberculosis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 44: China Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 45: China Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 46: China 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
TABLE 47: China Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 48: China Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 49: China 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
EUROPE
Tuberculosis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 50: Europe Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 51: Europe Historic Review for Tuberculosis Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 52: Europe 15-Year Perspective for Tuberculosis Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
TABLE 53: Europe Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 54: Europe Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 55: Europe 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
TABLE 56: Europe Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 57: Europe Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 58: Europe 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
FRANCE
Tuberculosis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 59: France Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 60: France Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 61: France 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
TABLE 62: France Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 63: France Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 64: France 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
GERMANY
Tuberculosis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 65: Germany Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 66: Germany Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 67: Germany 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
TABLE 68: Germany Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 69: Germany Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 70: Germany 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
ITALY
TABLE 71: Italy Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 72: Italy Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 73: Italy 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
TABLE 74: Italy Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 75: Italy Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 76: Italy 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
UNITED KINGDOM
Tuberculosis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 77: UK Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 78: UK Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 79: UK 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
TABLE 80: UK Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 81: UK Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 82: UK 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
SPAIN
TABLE 83: Spain Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 84: Spain Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 85: Spain 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
TABLE 86: Spain Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 87: Spain Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 88: Spain 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
RUSSIA
TABLE 89: Russia Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 90: Russia Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 91: Russia 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
TABLE 92: Russia Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 93: Russia Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 94: Russia 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
REST OF EUROPE
TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 96: Rest of Europe Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 97: Rest of Europe 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 99: Rest of Europe Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 100: Rest of Europe 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
ASIA-PACIFIC
Tuberculosis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 102: Asia-Pacific Historic Review for Tuberculosis Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 103: Asia-Pacific 15-Year Perspective for Tuberculosis Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 105: Asia-Pacific Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 106: Asia-Pacific 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 108: Asia-Pacific Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 109: Asia-Pacific 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
AUSTRALIA
Tuberculosis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
TABLE 110: Australia Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 111: Australia Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 112: Australia 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
TABLE 113: Australia Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 114: Australia Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 115: Australia 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
INDIA
Tuberculosis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
TABLE 116: India Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 117: India Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 118: India 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
TABLE 119: India Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 120: India Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 121: India 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
SOUTH KOREA
TABLE 122: South Korea Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 123: South Korea Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 124: South Korea 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
TABLE 125: South Korea Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 126: South Korea Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 127: South Korea 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
REST OF ASIA-PACIFIC
TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 129: Rest of Asia-Pacific Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 130: Rest of Asia-Pacific 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 132: Rest of Asia-Pacific Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
LATIN AMERICA
Tuberculosis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
TABLE 134: Latin America Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 135: Latin America Historic Review for Tuberculosis Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 136: Latin America 15-Year Perspective for Tuberculosis Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
TABLE 137: Latin America Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 138: Latin America Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 139: Latin America 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
TABLE 140: Latin America Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 141: Latin America Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 142: Latin America 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
ARGENTINA
TABLE 143: Argentina Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 144: Argentina Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 145: Argentina 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
TABLE 146: Argentina Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 147: Argentina Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 148: Argentina 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
BRAZIL
TABLE 149: Brazil Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 150: Brazil Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 151: Brazil 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
TABLE 152: Brazil Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 153: Brazil Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 154: Brazil 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
MEXICO
TABLE 155: Mexico Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 156: Mexico Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 157: Mexico 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
TABLE 158: Mexico Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 159: Mexico Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 160: Mexico 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
REST OF LATIN AMERICA
TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 162: Rest of Latin America Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 163: Rest of Latin America 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 165: Rest of Latin America Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 166: Rest of Latin America 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
MIDDLE EAST
Tuberculosis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
TABLE 167: Middle East Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 168: Middle East Historic Review for Tuberculosis Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 169: Middle East 15-Year Perspective for Tuberculosis Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
TABLE 170: Middle East Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 171: Middle East Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 172: Middle East 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
TABLE 173: Middle East Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 174: Middle East Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 175: Middle East 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
IRAN
TABLE 176: Iran Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 177: Iran Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 178: Iran 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
TABLE 179: Iran Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 180: Iran Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 181: Iran 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
ISRAEL
TABLE 182: Israel Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 183: Israel Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 184: Israel 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
TABLE 185: Israel Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 186: Israel Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 187: Israel 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
SAUDI ARABIA
TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 189: Saudi Arabia Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 190: Saudi Arabia 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 192: Saudi Arabia Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 193: Saudi Arabia 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
UNITED ARAB EMIRATES
TABLE 194: UAE Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 195: UAE Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 196: UAE 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
TABLE 197: UAE Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 198: UAE Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 199: UAE 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
REST OF MIDDLE EAST
TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 201: Rest of Middle East Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 202: Rest of Middle East 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 204: Rest of Middle East Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 205: Rest of Middle East 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030
AFRICA
Tuberculosis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
TABLE 206: Africa Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 207: Africa Historic Review for Tuberculosis Diagnostics by Type - Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 208: Africa 15-Year Perspective for Tuberculosis Diagnostics by Type - Percentage Breakdown of Value Sales for Culture based Diagnosis, Sputum Test, Rapid Molecular Diagnosis and Other Types for the Years 2015, 2025 & 2030
TABLE 209: Africa Recent Past, Current & Future Analysis for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 210: Africa Historic Review for Tuberculosis Diagnostics by End-Use - Hospitals, Diagnostic Labs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 211: Africa 15-Year Perspective for Tuberculosis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Labs and Other End-Uses for the Years 2015, 2025 & 2030